Hematologic adverse events
| . | Grade 2, % . | Grade 3, % . | Grade 4, % . |
|---|---|---|---|
| Anemia | 16 | ||
| Neutropenia | 10 | 3 | 1 |
| Thrombocytopenia | 1 | 1 | 1 |
| . | Grade 2, % . | Grade 3, % . | Grade 4, % . |
|---|---|---|---|
| Anemia | 16 | ||
| Neutropenia | 10 | 3 | 1 |
| Thrombocytopenia | 1 | 1 | 1 |
Overall, the number of patients with at least one AE grade 3/4 was 5 (7%), and the number of patients with at least on AE grade 2, 3, or 4, was 21 (29%). All the hematologic AEs were identified during the first quarter of therapy. Their identification was based on 431 blood counts which were due out of 438 counts (per protocol, blood counts and differentials were due every 15 days during the first quarter). The frequency of all grade 3/4 AEs reported in 280 CP patients who were treated with nilotinib second line32 was higher (29% neutropenia and thrombocytopenia, 10% anemia).